JP2011521897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521897A5
JP2011521897A5 JP2011505127A JP2011505127A JP2011521897A5 JP 2011521897 A5 JP2011521897 A5 JP 2011521897A5 JP 2011505127 A JP2011505127 A JP 2011505127A JP 2011505127 A JP2011505127 A JP 2011505127A JP 2011521897 A5 JP2011521897 A5 JP 2011521897A5
Authority
JP
Japan
Prior art keywords
peptide ligand
moiety
nanoparticle
fluorescent
ligand according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011505127A
Other languages
English (en)
Japanese (ja)
Other versions
JP5497006B2 (ja
JP2011521897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040480 external-priority patent/WO2009129220A2/en
Publication of JP2011521897A publication Critical patent/JP2011521897A/ja
Publication of JP2011521897A5 publication Critical patent/JP2011521897A5/ja
Application granted granted Critical
Publication of JP5497006B2 publication Critical patent/JP5497006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011505127A 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 Active JP5497006B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4481808P 2008-04-14 2008-04-14
US61/044,818 2008-04-14
PCT/US2009/040480 WO2009129220A2 (en) 2008-04-14 2009-04-14 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014042379A Division JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Publications (3)

Publication Number Publication Date
JP2011521897A JP2011521897A (ja) 2011-07-28
JP2011521897A5 true JP2011521897A5 (enExample) 2012-07-05
JP5497006B2 JP5497006B2 (ja) 2014-05-21

Family

ID=41199683

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011505127A Active JP5497006B2 (ja) 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Country Status (6)

Country Link
US (4) US8829159B2 (enExample)
EP (2) EP2265630B1 (enExample)
JP (3) JP5497006B2 (enExample)
CA (1) CA2758415C (enExample)
HK (1) HK1209438A1 (enExample)
WO (1) WO2009129220A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5497006B2 (ja) * 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2013510094A (ja) * 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
DE102010039289A1 (de) * 2010-08-12 2012-02-16 Leica Microsystems (Schweiz) Ag Mikroskopsystem
WO2013071239A1 (en) * 2011-11-10 2013-05-16 Exosome Diagnostics, Inc. Cerebrospinal fluid assay
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
US10860526B2 (en) * 2012-12-01 2020-12-08 The Regents Of The University Of California System and method of managing large data files
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
US20160166715A1 (en) * 2013-07-30 2016-06-16 Tarveda Therapeutics, Inc. Nanoparticle Diagnostic and Methods for Treating Disease
WO2015054243A1 (en) * 2013-10-07 2015-04-16 Van Dam, Jacques Integrated ultrasound, oct, pa and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts
US10668125B2 (en) 2015-11-19 2020-06-02 Niigata University Peptide having highly-shifted accumulation to pancreatic cancer cells and tissues, and use of said peptide
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
JP7197078B2 (ja) * 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
CA3021140A1 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN109963875A (zh) * 2016-10-26 2019-07-02 西尔欧集团 靶向并通过辐射能分解癌症的癌症结合不透射线肽类
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
CN112105380A (zh) * 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
MX2020004530A (es) * 2017-11-18 2020-09-18 Magalhaes Nzola De Producto y proceso para emplear conjugados de union a antigeno basados en gc7 (n1-guanil-1,7-diaminoheptano) en terapia de cancer.
US11890352B2 (en) 2018-02-27 2024-02-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
US11358984B2 (en) 2018-08-27 2022-06-14 Regeneran Pharmaceuticals, Inc. Use of Raman spectroscopy in downstream purification
EP3895733A4 (en) * 2018-12-14 2022-03-02 Konica Minolta, Inc. METHOD OF PREDICTING THE ARRIVAL OF A DRUG WITHIN DISEASED TISSUE
CN114814200B (zh) * 2022-05-09 2025-06-27 浙江大学 一种纳米颗粒-荧光标记融合蛋白复合体及其单链dna检测方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
WO1985003508A1 (en) 1984-02-08 1985-08-15 Cetus Corporation Toxin conjugates
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
FI954559A7 (fi) 1993-03-29 1995-09-26 Univ Cincinnati YY-peptidin analogit ja niiden käytöt
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
ATE264694T1 (de) 1995-01-30 2004-05-15 Daiichi Pure Chemicals Co Ltd Diagnostisches markierungsmittel
US20030100051A1 (en) * 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US20030103975A1 (en) * 1999-11-03 2003-06-05 Jones Jonathan C.R. Modulation of angiogenesis and endothelialization
US20030069180A1 (en) * 2000-06-09 2003-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AUPR290801A0 (en) * 2001-02-06 2001-03-01 Peter Maccallum Cancer Institute, The Substrate binding domain
AU2002320058A1 (en) * 2001-06-06 2002-12-16 The General Hspital Corporation Magnetic-nanoparticle conjugates and methods of use
WO2003030725A2 (en) * 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20050249668A1 (en) * 2002-03-29 2005-11-10 Ralph Weissleder Nir-fluorescent cyanine dyes, their synthesis and biological use
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US20050095611A1 (en) * 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
US8815235B2 (en) * 2004-06-02 2014-08-26 Jan E. Schnitzer Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
ES2360519T3 (es) * 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
EP2005187A4 (en) * 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
JP5497006B2 (ja) * 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
WO2010068864A2 (en) * 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions

Similar Documents

Publication Publication Date Title
JP2011521897A5 (enExample)
Nguyen et al. Recent progress and challenges of MOF-based nanocomposites in bioimaging, biosensing and biocarriers for drug delivery
Hong et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene
Wang et al. Hypoxia-active nanoparticles used in tumor theranostic
AU2019232847B2 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
JP6510494B2 (ja) 腎薬物標的化のためのペプチドおよびペプチド−活性成分の接合体
Luque-Michel et al. Clinical advances of nanocarrier-based cancer therapy and diagnostics
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
CN114340610A (zh) 多价成纤维细胞靶向剂及使用方法
Liu et al. An integrative folate-based metal complex nanotube as a potent antitumor nanomedicine as well as an efficient tumor-targeted drug carrier
Rizvi et al. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Duan et al. Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
Rajasekharreddy et al. Green synthesized nanomaterials as theranostic platforms for cancer treatment: Principles, challenges and the road ahead
Chen et al. A fast tumor‐targeting near‐infrared fluorescent probe based on bombesin analog for in vivo tumor imaging
Huang et al. Nano-based theranostic approaches for infection control: current status and perspectives
Hou et al. Advancements and challenges in the application of metal-organic framework (MOF) nanocomposites for tumor diagnosis and treatment
Wang et al. Recent progress in functional peptides designed for tumor-targeted imaging and therapy
CN110420337A (zh) 一种靶向整合素α6的二聚体多肽放射性药物及其制备方法
WO2016150521A1 (en) Functionalised magnetic nanoparticle
Rerat et al. Ultrasmall particle of iron oxide—RGD peptidomimetic conjugate: synthesis and characterisation
Kaur et al. An Overview of Structural Framework and Classification of Theranostic Radiopharmaceuticals
JP6848015B2 (ja) 放射性元素の標識方法、放射性標識化合物、及びそれを含む放射性元素標識キット
Wang et al. Advances in nanomedicine and delivery systems for gastric cancer research
Giblin et al. In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers
Vavsari et al. Technetium-99m-labeled peptides and their applications in radio imaging: advancements in Latin American research